Interleukin-12 gene therapy for hepatocellular carcinoma: A dream come true?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 10, 2004, Pages 1097-1100

  Tsai, Sun Lung ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12;

CANCER THERAPY; CELLULAR IMMUNITY; EDITORIAL; GENE THERAPY; GENETIC ENGINEERING; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOTHERAPY; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR CELL;

EID: 5644299008     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03552.x     Document Type: Editorial

References (38)

1. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992; 15: 948-63.
2. Farmer DG, Rosove MH, Shaked A, Busuttil RW. Current treatment modalities for hepatocellular carcinoma. Ann. Surg. 1994; 219: 236-47.
3. Tatsumi T, Takehara T, Kanto T et al. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma. Hepatology 1999; 30: 422-9.
4. Drozdzik M, Qian C, Xie X et al. Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma. J. Hepatol. 2000; 32: 279-86.
5. Pützer BM, Stiewe T, Rödicker F et al. Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/ B7.1 genes. J. Natl Cancer Inst. 2001; 93: 472-9.
6. Wang Z, Qiu SJ, Ye SL, Tang ZY, Xiao X. Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma. Cancer Gene Ther. 2001; 8: 751-8.
7. Yamashita YI, Shimada M, Hasegawa H et al. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res. 2001; 61: 1005-12.
8. Barajas M, Mazzolini G, Genové G et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 2001; 33: 52-61.
9. Himoto T, Watanabe S, Nishioka M, Tanaka S, Saito M. Combination immunotherapy with OK432, recombinant granulocyte-colony stimulating factor and recombinant interleukin-2 for human hepatocellular carcinoma. Cancer Immunol. Immunother. 1996; 42: 127-31.
10. Boon T, Cerrotini JC, Van den Eynde B, Van den Bruggen B, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 1994; 2: 337-65.
11. Schultze JL, Vonderheide RH. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol. 2001; 22: 516-23.
12. Zitvogel L, Robbins PD, Storkus WJ et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol. 1996; 26: 335-41.
13. Sun Y, Qian C, Peng D, Prieto J. Gene transfer to liver cancer cells of B7-1 plus interleukin 12 changes immunoeffector mechanisms and suppresses helper T cell type 1 cytokine production induced by interleukin 12 alone. Hum. Gene Ther. 2000; 11: 127-38.
14. Kang WK, Park C, Yoon HL et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum. Gene Ther. 2001; 12: 671-84.
15. Gately MK, Renzetti LM, Magram J et al. The interleukin-12/ interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 1998; 6: 495-521.
16. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001; 106: 263-6.
17. Melero I, Duarte M, Ruiz J et al. Intratumoral injection of bone marrow- derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther. 1999; 6: 1779-84.
18. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 1999; 59: 4035-41.
19. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
20. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001; 106: 271-4.
21. Bottomly K. T cells and dendritic cells get intimate. Science 1999; 283: 1124-5.
22. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin 12 is mediated by the interferon-inducible protein 10. Blood 1996; 87: 3877-82.
23. Pockros PJ, Patel K, O'Brien C et al. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. Hepatology 2003; 37: 1368-74.
24. Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000; 32: 604-9.
25. Tsai SL, Sheen IS, Chien RN et al. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J. Biomed. Sci. 2003; 10: 120-35.
26. Tsai SL, Lee TH, Chien RN et al. A method to increase tetramer-staining efficiency of CD8+ T cells with MHC-peptide complexes: therapeutic applications in monitoring cytotoxic T lymphocyte activity during hepatitis B and C treatment. J. Immunol. Meth. 2004; 285: 71-87.
27. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25: 449-58.
28. Lenzi R, Rosenblum M, Verschraegen C et al. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin. Cancer Res. 2002; 12: 3686-95.
29. Robertson MJ, Pelloso D, Abonour R et al. Interleukin-12 immunotherapy after autologous stem cell transplantation for hematological malignancies. Clin. Cancer Res. 2002; 11: 3383-93.
30. Rook AH, Zaki MH, Wysocka M et al. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann. NY Acad. Sci. 2001; 941: 177-84.
31. Melero I, Mazzolini G, Narvaiza I, Qian C, Chen L, Prieto J. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol. 2001; 22: 113-15.
32. Jonathan C, Jager E, Shackleton MJ et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immunity 2003; 3: 7-25.
33. Gollob JA, Veenstra KG, Parker RA et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J. Clin. Oncol. 2003; 21: 2564-73.
34. Ren H, Boulikas T, Soling A, Warnke PC, Rainov NG. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene - a phase I/II clinical protocol. J. Neurooncol. 2003; 64: 147-54.
35. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 2001; 22: 269-76.
36. Shevach EM. CD4+CD8+ suppressor T cells: more questions than answers. Nature Rev. Immunol. 2002; 2: 389-400.
37. Bach JF. Regulatory T cells under scrutiny. Nature Rev. Immunol. 2003; 3: 189-98.
38. Peron JM, Couderc B, Rochaix P et al. Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12. J. Gastroenterol. Hepatol. 2004; 19: 388-96.